Genetic and Ontogenetic Variation in Response to Scopolamine and D-amphetamine in Three Strains of Mice by Remington, Gary
Wilfrid Laurier University 
Scholars Commons @ Laurier 
Theses and Dissertations (Comprehensive) 
1974 
Genetic and Ontogenetic Variation in Response to Scopolamine 
and D-amphetamine in Three Strains of Mice 
Gary Remington 
Wilfrid Laurier University 
Follow this and additional works at: https://scholars.wlu.ca/etd 
 Part of the Biological Psychology Commons 
Recommended Citation 
Remington, Gary, "Genetic and Ontogenetic Variation in Response to Scopolamine and D-amphetamine in 
Three Strains of Mice" (1974). Theses and Dissertations (Comprehensive). 1605. 
https://scholars.wlu.ca/etd/1605 
This Thesis is brought to you for free and open access by Scholars Commons @ Laurier. It has been accepted for 
inclusion in Theses and Dissertations (Comprehensive) by an authorized administrator of Scholars Commons @ 
Laurier. For more information, please contact scholarscommons@wlu.ca. 
Genetic and Ontogenetic Variation in Response 
to Scopolamine and D - amphetamine 
in Three Strains of Mice 
Gary Remington 
Thesis presented to the Faculty of Graduate Studies 
of Wilfrid Laurier University in partial fulfillment 
of the requirements for the degree of Master 
of Arts in Psychology 
UMI Number: EC56387 
All rights reserved 
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent on the quality of the copy submitted. 
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed, 
a note will indicate the deletion. 
UMT 
Dissertation Publishing 
UMI EC56387 
Copyright 2012 by ProQuest LLC. 
All rights reserved. This edition of the work is protected against 
unauthorized copying under Title 17, United States Code. 
uest* 
ProQuest LLC. 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346 
(c) Gary Remington 
I hereby declare that I am the sole author 
of this thesis. I authorize Wilfrid Laurier 
University to lend it to other institutions 
or individuals for the purpose of scholarly 
research. 
Acknowledgements 
Appreciation is extended to Hymie Anisman for help here and 
there (sometimes more there than here), Sid Hellyer, Alan Auerbach, and 
Cam McRae for helpful suggestions and hopefully kind critiques, and 
Lucy Johnson for moral support. 
Thanks are also due to Smith, Klein and French Inc. for 
supplying d-amphetamine sulfate; Department of Psychology, University 
of Waterloo for the use of facilities and supplies; Medical Research 
Council of Canada (Research on Drug Abuse) for support during the latter 
phases of the project. 
The research was supported by Grant A9845 from the National 
Research Council of Canada to Hymie Anisman. 
iii 
Abstract 
Highly inbred mice of three strains (A/J, DBA/2J and C57BL/6J) were 
tested in an activity task at 14, 21, or 28 days of age. Ten minutes 
prior to testing, mice received treatment of either saline, scopolamine 
(0.5 or 1.0 mg/kg) or d-amphetamine (0.5, 1.0 or 5.0 mg/kg). At 14 days 
of age DBA mice exhibited higher levels of activity than either A or C57 
mice. However, the increase in activity in C57 was such that at 21 and 
28 days no difference was observed relative to DBA mice, and activity 
was higher than that of A mice. With respect to the drug treatments, 
d-amphetamine (5.0 mg/kg) increased activity in all strains at 14 days and 
28 days of age. At 21 days, only C57 exhibited lack of a significant 
increase in activity. Clearly, the system responsible for responsivity 
to d-amphetamine (dopamine and norepinephrine) is mature at 14 days of age. 
In contrast to d-amphetamine, a response to scopolamine was evident in DBA 
at 21 days of age, and in C57 and A at 28 days of age. These data were 
taken to support a caudal-rostral gradient of brain development, with the 
inhibitory cholinergic system developing more slowly than the excitatory 
catecholamine system. Moreover, there also appears to be strain-specific 
differences in neuronal development. The differential development of the 
cholinergic system, together with potential differences in the ontogeny of 
the catecholamine system, were suggested as being responsible for age 
dependent variations in activity, as well as differential responsivity to 
pharmacological agents which increase catecholamine activity. 
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INTRODUCTION 
There is little debate regarding the degree of maturity of the central 
•v- •- »nervous system at birth. While considerable organization and proliferation 
of neurons occurs prenatally, very rapid growth and development of synaptic 
junctions occur in cortical and subcortical areas in the rat and mouse 
brain during the third and fourth postnatal weeks (Aghajanian & Bloom, 1967). 
In addition, rapid dendritic growth in the mouse brain has been recorded 
between 8 and 15 days postnatally (Himwich, 1970). Similarly, the maturation 
of neurotransmitter systems probably approximates the sequence of synaptic 
development, since the storage and release of these endogenous chemicals are 
directly related to presynaptic functioning (Axelrod, 1970). Indeed, Keller, 
Bartholini, and Pletscher (1973) , Lander and Bloom (1974) , Loizou (1971), 
and Loizou and Salt (1970) have identified increased levels of brain mono-
amines in close temporal proximity to the proliferation of axon terminals of 
monoamine containing neurons. Although most rapid ontogenesis of the central 
nervous system occurs during the third and fourth postnatal weeks, further 
development continues up to at least one year of age (Pscheidt & Himwich, 
1966). Of course, the precise nature of the growth is species dependent, 
with precocial organisms such as the guinea pig (Bennett & Giarman, 1965) 
and chick (Pscheidt & Himwich, 1966) showing greater prenatal development 
than that seen in altricial organisms such as the rat (Eiduson, 1971). 
Unlike the development of the peripheral nervous system, which follows 
a proximo-distal and cephalo-caudal pattern, numerous studies have indicated 
agreement with the Jacksonian model of brain organization (Jackson, 1931). 
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That is, there exists a caudal-rostral gradient of brain development with 
the higher (rostral) regions developing more slowly than the lower (caudal)-• 
regions-(Eiduson, 1971; Kim, Choi, Kim, Chang, Park, & Kang, 1970; 
Moorcroft, 1971). Moreover, it is well known that the rostral structures, 
such as the limbic forebrain (including septum, hippocampus, and amygdala) 
are largely modulated by acetylcholine which inhibits ongoing activity, 
while caudal areas, such as hypothalamus, are exceptionally rich in 
catecholamines (dopamine and norepinephrine) which tend to have excitatory 
effects. Areas between these structures, such as the caudate-putamen, 
contain large amounts of both acetylcholine and dopamine (Cooper, Bloom, 
& Roth, 1970). In effect, the suggestion has been that the inhibitory 
cholinergic system may interact, either in an additive or synergistic 
manner, with the excitatory catecholaminergic system (Campbell & Mabry, 
1973; Carlton, 1963, 1969; Feigley, 1974; Moorcroft, Lytle, & Campbell, 
1971). 
With respect to the development of the neurotransmitter systems, several 
researchers have documented the slower development of cholinergic pathways 
than of pathways involving catecholamines, with particular reference to 
norepinephrine. These observations have come primarily from experiments 
evaluating enzymatic activity associated with various transmitters in both 
rats (Coyle & Axelrod, 1972a, 1972b; Loizou, 1971; McGeer, Fibiger, & 
Wickson, 1971; Mellgren, 1973; Porcher & Heller, 1972) and mice (Baker, 
Hoff, & Smith, 1973). For example, it has been observed that levels of 
monoamine oxidase (MAO), the enzyme which degrades monoamines (dopamine, 
norepinephrine, and serotonin) intracellularly, dopamine-g-hydroxylase, 
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the enzyme involved in the conversion of dopamine into norepinephrine 
(Coyle & Axelrod, 1972a), as well as tyrosine hydroxylase, the rate 
limiting step in the synthesis of catecholamines (Coyle & Axelrod, 1972b; 
Porcher & Heller, 1972), increase during postnatal development (Baker & 
Hoff, 1972; Coyle & Axelrod, 1971; Haber & Kamano, 1966; Iverson, 
de Champlain, Glowinski, & Axelrod, 1967; Loizou & Salt, 1970; Robinson, 
1968). Of course, the presence and effectiveness of the various neuro-
transmitters is related to the functional maturity of these enzymes. 
The presence of these enzymes appears in detectable quantities in the 
rodent brain at 15 days of gestation. In contrast, enzymes associated 
with acetylcholine synthesis or degradation (choline acetyltransferase 
and acetylcholinesterase, respectively) reach adult levels between 15 
and 20 days of age postnatally (Hatcori & McGeer, 1971), clearly revealing 
slower development than enzymes associated with the azdnes (McGeer et al, 
1971; see also Ladinsky, Consolo, Peri, & Garattini, 1972). While the 
data regarding enzymatic ontogeny have been useful in elucidating neuronal 
and neurochemical development, a number of studies have been reported which 
demonstrate that responsivity to pharmacological treatments may similarly 
lend themselves to ontogenic analysis of endogenous chemicals, as well 
as their role in the maturation of behaviour (Campbell, Lytle, & Fibiger, 
1969; Fibiger, Lytle, & Campbell, 1970; McGeer et al, 1971; Thornburg & 
Moore, 1973). This particular technique has three advantages over the 
biochemical assays described, the first simply being that the research can 
be carried out more quickly and efficiently. Secondly, pharmacological 
effects of various treatments can be evaluated concomitantly, and finally, 
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interactions among various systems can be detected. In the following 
sections, investigations of this nature, together with their rationale, are 
documented. 
Behavioural Effects of Acetylcholine and Catecholamines 
It has been reported by a number of investigators that modifications 
of neurotransmitter levels by pharmacological manipulation have profound 
effects on a number of behavioural measures. For example, agents which 
effectively decrease levels of acetylcholine, such as scopolamine and 
atropine, tend to enhance active avoidance (Anisman, 1973; Anisman, 1974a; 
Anisman & Kokkinidis, 1974; Bignami & Rosic, 1971; Bignami, Amorico, 
Frontali, & Rosic, 1971; Carlton, 1962; Carlton & Markiewicz, 1971; Safer 
& Allen, 1970) increase levels of general activity (Anisman, 1974b; Anisman, 
Wahlsten, & Kokkinidis, 1974; Payne & Anderson, 1967; Schwartzbaum, 
Ide-Johanson, & Belgrade, 1974), decrease passive avoidance (Feigley, 1974), 
and eliminate or reduce habituation tendencies (Anisman, 1974b; Anisman 
& Kokkinidis, 1974; Carlton, 1961; Carlton & Vogel, 1965). The converse 
is true of agents which increase levels of acetylcholine e.g. physostigmine 
or pilocarpine (see, for example, Anisman, 1974; Bignami & Rosic, 1970; 
Bignami, Rosic, Mickalek, Milosevic, & Gatti, 1974, in press). Manipulations 
of dopamine and norepinephrine have also been observed to modify behaviour. 
Decreasing levels of these amines tends to disrupt avoidance and reduce 
locomotor activity (Cooper, Grant, & Breese, 1973; Costa & Groppetti, 
1970; Ellison & Bresler, 1973; Fibiger, Fibiger, & Zis, 1973; Herman, 
Trzeciak, Chrusciel, Kmieciak-Kolada, Drybanski, & Sokola, 1971; Neill, 
Boggan, & Grossman, 1974), while increases in catecholamine activity with 
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drugs such as amphetamine (Goodman & Gillman, 1965) augment avoidance 
performance and increase general activity (Anisman, 1974a; Axelrod, 1974; 
Bindra & Baran, 1959; Bindra & Mendelson, 1963; Cole, 1967-; Grossman & 
Scalfani, 1971; Rech & Stolk, 1970; Van Rossum, 1970; see reviews in 
Costa & Garattini, 1971). Moreover, over the past few years, advances 
have been made in differentiating behavioural properties of dopamine and 
norepinephrine. For example, dopamine appears to be involved in producing 
stereotypic behaviours (Anden, Srombom, & Svenson, 1973; Fog, Randrup, 
& Pakkenberg, 1967, Molander & Randrup, 1974; Randrup & Munkvad 
1967, 1968, 1970) and in modulating activity levels (Maj, Grabowska, 
& Mogilnicka, 1971; Thornburg & Moore, 1973; Ungerstedt, 1971, 1974). 
Norepinephrine is also involved in moderating activity, but to a lesser 
extent than that of dopamine (Dominic & Moore, 19 71; Rolinski & Scheel-
Kruger, 1973), and is also involved in changes in activity levels with the 
inception of stressors (Anisman & Cygan, 1974).
 %These conclusions are 
based on numerous studies indicating that synthesis inhibition of dopamine 
and norepinephrine, via a-methyltyrosine, completely abolishes the excitatory 
effects of amphetamine. However, inhibition of norepinephrine, while 
leaving dopamine synthesis intact, by bis-(4-methyl-l-homopiperazinylthio-
carbonyl) disulphide (FLA-63), the inhibitor of dopamine-^-hydroxylase, 
has lesser effects on increases in activity promoted by amphetamine 
(Carlsson, 1970). Some of the more recent positions have involved the 
suggestion that dopamine, in fact, modulates activity levels; however, this 
is dependent on the presence of adequate levels of norepinephrine (Carlsson, 
1970). 
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In light of the polar effects of cholinergic and noradrenergic drugs, 
it has been suggested that a distinct balance exists between the cate-
cholamine excitatory system (dopamine and norepinephrine) and the inhibitory 
cholinergic system (Carlton, 1963, 1968, 1969; McGeer et al, 1971). 
According to this hypothesis, there exists a cholinergic mechanism in 
the brain that antagonizes a dopaminergic and/or noradrenergic system, 
which is excitatory. The notion that these 2 systems act in a specific 
balance is strongly supported by studies involving drug interactions. 
For example, it has been demonstrated that low, normally non-effective 
doses of scopolamine can augment the action of amphetamine in increasing 
responses within an active avoidance situation (Carlton, 1961; Carlton 
& Didamo, 1961). Furthermore, it has been found that cholinomimetic 
drugs, such as pilocarpine, decrease amphetamine induced psychomotor 
excitation in rats (Carlton, 1961). Evidence has been gathered which 
would suggest that there is an interaction between peripheral epinephrine 
effects and the central cholinergic and noradrenergic systems. Specifically, 
injections of scopolamine are able to prevent reductions in motor activity 
and avoidance ordinarily elicited by epinephrine (Manto, 1967; Remington 
& Anisman, 1974). 
Summarizing then, there are ample data indicating that the cholinergic 
system inhibits active behaviours while the catecholamine system activates 
these behaviours. Moreover, these systems act in a reciprocal antagonistic 
manner. Extension of these studies involving direct application of anti-
cholinergics to limbic structures (Abeelen, Smits, & Raaijmakers, 1970; 
Abeelen, Gilissen, Hanssen & Lenders, 1971; Grossman, 1962, 1964; Grossman 
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& Scalfani, 1971), or dopaminergic and noradrenergic agents to the substantia 
nigra and hypothalamus, respectively (Fibiger et al, 1973; Grossman & 
Scalfani, 1971) have yielded results comparable to those witnessed with 
systemic injections. Such studies have thus implicated these structures as 
being involved in inhibitory or excitatory processes, and have clearly 
shown the drug actions to be primarily of a central rather than a peripheral 
nature. 
Ontogeny of Behaviour: Pharmacological Manipulations 
From a behavioural vantage, the available data have supported the 
Jacksonian model of brain organization, and have also implicated 
catecholamine and acetylcholine ontogeny as factors in modulating 
age-dependent changes in behaviour. For example, in precocial organisms 
such as the guinea pig (Campbell & Mabry, 1972; Hirsrich, 1970; Karki, 
Kuntzman, & Brodie, 1962) and chick (Campbell & Mabry, 1972; Masai, 
Kusunoki & Ishibashi, 1965), where the brain is fairly well developed at 
birth, little variation in activity levels is seen from 5 to 100 days of 
age. In contrast, among altricial organisms such as the rat (Moorcroft 
et al, 1971) or hamster (Campbell & Mabry, 1972), a sizeable increase in 
activity is observed between 10 and 15 days postpartum, followed by a 
substantial decline in activity between 15 and 25 days of age. It will be 
recalled that these ages are roughly comparable to the caudal-rostral 
pattern of brain development in which the inhibitory telencephalic centres 
mature later than the brain stem excitatory areas. Surgical manipulation 
of various brain structures have substantiated the role of limbic and 
hypothalamic structures in the ontogenic variations in locomotor behaviour. 
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That is, surgical removal of the hippocampus, which appears to be a major 
axis for acetylcholine activity (Kelsey & Grossman, 1969; Lewis, Shute, & 
.,. JSilver, 1967; Lynch, Mathews, Mosko,.Parks & Cotman", 1972; Macadar, Roig, 
Monti & Buddeli, 1970; Mellgren & Srebro, 1973), does not appear to affect 
behaviour in the rat prior to 21 days of age, but produces marked increases 
in activity among adult animals (Moorcroft, 1971). 
In terms of responsivity to drug treatments, it has been observed 
repeatedly that administration of amphetamine augments activity levels in 
rats as early as 10 days of age, whereas scopolamine, which blocks cholinergic 
action, is without effect until 20 days of age. Moreover, these effects do 
not appear to involve peripheral cholinergic action, since the quarternary 
congener of scopolamine (i.e. methyl-scopolamine), which does not pass into 
the brain, fails to affect activity levels (Anisman & Kokkinidis, 1974; 
Campbell et al, 1969; Feigley, 1974). In addition, benztropine, a potent 
anticholinergic which resembles scopolamine both structurally and pharma-
cologically (Thornburg & Moore, 1973), produces similar results, suggesting 
that the observed effects are not specific to scopolamine alone. Confirma-
tion and extension of these results have come from additional studies by 
Fibiger et al, (1970) , in which it was observed that the typical antagonism 
of the amphetamine effects by pilocarpine ( a cholinomimetic) was not 
apparent in rats younger than 20 days of age. Similarly, the synergism 
between d-amphetamine and scopolamine is not apparent at 10 days of age, but 
is present in the 30-day-old rat (McGeer et al, 1970). Clearly, it would 
appear that a balance exists between the catecholaminergic and 
cholinergic systems; however, the interaction between these transmitters 
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is not in effect until adequate maturation of the cholinergic system has 
taken place. 
Greater specificity regarding catecholamine ontogenesis has come 
recently from studies attempting to divorce the actions of the dopamine 
and norepinephrine systems. Specifically, it has been reported (Lamprecht 
& Coyle, 1972) that the norepinephrine system develops somewhat slower 
than does the dopamine system. Although the enzymes involved in the 
conversion of dopa to dopamine (dopa decarboxylase) and dopamine to norepine-
phrine (dopamine-3-hydroxylase) progress equally quickly, the lag in 
norepinephrine appears to be related to a deficiency of vesicular storage. 
Further studies have suggested that both the norepinephrine and the dopamine 
systems are mature at day one of age, but may possibly differ in terms of the 
development of the receptor cells. Specifically, L-dopa, which increases 
dopamine and norepinephrine activity, produces behavioural excitation as 
early as one day following birth. Similarly, clonidine, a norepinephrine 
receptor stimulating agent, elicits a behavioural response similar to that 
seen with L-dopa. In contrast, responsivity to a dopamine receptor 
stimulating agent,apomorphine, is not observed until 3-4 days postpartum. 
Evidently, the production of both dopamine and norepinephrine differs by 
only a small amount, but the age at which the receptors mature varies 
by several days (Kellogg & Lundborg, 1972). It may well be the case 
that the catecholamine interaction with the forebrain cholinergic centres 
may involve both dopamine and norepinephrine. The precise specificity 
as to which is predominant i.e. dopamine or norepinephrine, is not clear 
since synthesis inhibition or depletion, as well as replenishment of 
either transmitter, have comparable effects (Campbell & Mabry, 1973). 
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Accordingly, both these amines may be equally important regarding potential 
interaction with acetylcholine. Summarizing then, the pharmacological 
approach to the understanding of the ontogenesis of the nervous system has 
yielded results comparable to that observed through autoradiographic 
and histological methods. Of equal importance, these data have also 
suggested that hyperactivity (or hyperreactivity) seen in immature animals 
may well be due to retarded cholinergic development. That is, when the 
cholinergic system is functional, the excitatory effects of the catecholamine 
system are dampened. However, so long as the inhibitory cholinergic system 
is not developed, activity levels are under control of the excitatory 
catecholamine systems. Thus, Campbell et al (1969) have postulated that 
the rapid rise in activity levels between 10 and 20 days of age is due to 
increased catecholamine activity, whereas the gradual decline in spontaneous 
activity following 20 days of age is due to the development of the inhibitory 
cholinergic system. This notion is discussed in greater detail in the 
following section. 
Experimental-Clinical Implications 
The concept of a noradrenergic-cholinergic model, with the noradrenergic 
system maturing more rapidly than the cholinergic system presents a viable 
framework for a theory of hyperactivity in the developing organism. In 
terms of human behaviour, it has been reported that severe hyperkinesis, 
as defined by chronic excessive levels of motor activity (Werry, 1968), has 
been estimated in at least 4% of all school-age children (Weiss, Minde, 
Douglas, Werry, & Sikes, 1967). This behavioural disorder has been 
referred to by a number of names including "hyperkinetic behaviour disorder", 
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"minimal brain dysfunction" (MBD), and "hyperactivity" (Grinspoon & 
Singer, 1973). The symptamology of the syndrome has been noted to include 
extreme overactivity, distractibility, short attention span, impulsiveness," 
marked mood fluctuations, and aggression (Eisenberg, 1972). The pharma-
cological and morphological evidence presented earlier on the differential 
development of the two systems associated with the motor activity suggests 
a possible link between biochemical development and the presence of a 
hyperkinetic syndrome. For example, the notion of delayed brain maturation 
is compatible with the empirical observation that hyperkinesis tends to 
improve with age (Millichap & Fowler, 1967). As such, it may well be the 
case that in the hyperkinetic child, there exists a retarded development 
of the cholinergic system, or overactivity of the catecholamine system. 
In fact, Wender (1974) has postulated that minimal brain dysfunction not 
only involves monoamine disturbances, but also generic factors which may 
be responsible for these aberrant levels of neurotransmitters. 
One disconcerting finding regarding the hyperkinetic syndrome is that 
administration of sympathomimetics such as amphetamine and ritalin, which 
in non-hyperkinetic children increase motility, result in a diminution of 
the hyperkinesis (Conners, 1970; Eisenberg, 1971; Millichap, 1968; Tec & 
Levy, 1971). Several possibilities exist which may account for the 
paradoxical effects of sympathomimetics in the hyperkinetic child. 
Specifically, where there exists an imbalance between noradrenergic and 
cholinergic activity, further increases in catecholamine action may result 
in a rebound involving yet a third system (e.g. serotonin) which inhibits 
the catecholamine effects (Swonger & Rech, 1972). Secondly, amphetamine 
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may produce end-product-inhibition, thus resulting~in decreased synthesis of 
dopamine and norepinephrine (Cooper et al, 1970). Finally, amphetamine may 
result in release of catecholamines frpm,storage granules^ thereby leaving 
the organism with reduced levels of functionally effective amines (Welch 
& Welch, 1970). Such an effect would occur when utilization of amines 
exceeds total biosynthesis. 
Turning again to the animal literature, several findings have been 
reported which are, in some respects, comparable to that seen in the 
human hyperkinetic syndrome. Specifically, it is well known that although 
activity increases with amphetamine, the extent of the increase is 
inversely proportional to baseline activity (Anisman et al, 1974; Fuller, 
1970; Glick & Malloy, 1973; Mosser & Welch, 1973). Yet, in the experiments 
carried out to date, there has neither been a developmental approach to 
hyperkinesis in animals, nor has there been an attempt to employ animals 
exhibiting behaviour resembling hyperactivity. To this end, the present 
experiment represents an attempt to employ a possible animal analogue to 
the hyperactive syndrome seen in the developing human. For example, it 
has been observed that the C57BL/6 strain of mice exhibit a relatively low 
level of acetylcholine (Ebel, Hermetet, & Mandel, 1972; Pryor, Schlesinger, 
& Calhoun, 1966), as well as exceptionally low cognitive abilities (Anisman, 
1974e). Moreover, general activity is greater in C57 mice than in the DBA 
strain, which in turn is greater than that of A mice (Anisman et al, 1974). 
It follows that the increased levels of activity seen in the C57 strain 
might be a function of low levels of acetylcholine and a related 
ineffectiveness of the cholinergic inhibitory system. Injections of an 
anticholinergic, such as scopolamine, should result in increased levels of 
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activity in those animals where large reductions in the system are possible, 
but should be relatively ineffective in animals with already reduced 
cholinergic levels. This hypothesis has in fact been supported, in that 
scopolamine has been shown to decrease levels of activity in the C57 strain 
(Abeelen & Strijbosch, 1969; Abeelen et al, 1970, 1971; Anisman et al, 1974; 
Oliverio, Eleftheriou, & Bailey, 1973). In contrast, d-amphetamine, a 
noradrenergic agent, uniformly increases activity levels in all three strains; 
however, this increase is inversely related to baseline activity levels. 
A second pint of interest in studies involving C57 mice is that this 
strain undergoes what has been termed a "popcorn" stage of activity at 
approximately 21 days of age (Anisman, unpublished observations; Wahlsten, 
unpublished observations). This period is evidenced by heightened loco-
motor activity and exaggerated reactions to novel stimuli, after which 
activity decreases; furthermore, this increase coincides with increased 
levels of norepinephrine in these animals (Schlesinger & Griek, 1970). 
However, in other strains of mice (i.e. A and DBA), this rise in locomotor 
activity is not observed, and they also exhibit lower levels of norepine-
phrine during this period of growth. It may well be the case that the 
"popcorn" stage of development is one in which the noradrenergic and 
cholinergic systems are at greatest imbalance, thus leading to the observed 
hyperkinesis. Accordingly, it may be possible to promote a retardation 
of activity levels at this age via drugs which at other times in development 
would augment motility. 
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Given the apparent congruency between the human hyperkinetic syndrome 
and that seen in mice, it would seem that a study involving genetic and 
ontogenic variables in response to pharmacological treatments might be a 
viable approach to the understanding of the etiology of human hyperkinesis. 
The present study represents an attempt to further investigate the noradrener-
gic and cholinergic developmental sequence in three strains of mice. Since 
the noradrenergic and cholinergic mechanisms differ in their rate of 
maturity (Campbell et al, 1960; Feigley, 1974; Fibiger et al, 1970), 
examination of drug effects at different ages presents an opportunity to 
determine whether observed increases in locomotor activity are a function 
of increased noradrenergic levels or initial low levels of cholinergic 
action. Since amphetamine is known to act upon the noradrenergic system 
(Houser & Van Hart, 1973; Javoy, Thierry, Kety, & Glowinski, 1968; Moore 
& Lariviere, 1963; Schildkraut & Kety, 1967; Taylor & Snyder, 1970), it 
is possible to administer such a drug at different ages postnatally to 
evaluate the maturation of this system. The use of the dextro-isomer of 
amphetamine (d-amphetamine) rather than the levo-isomer (1-amphetamine) 
is indicated by evidence that the former is a markedly more potent 
excitator of norepinephrine, while the levo-isomer is equipotent to the 
dextro-isomer in modifying dopamine action. Behaviourally, it has been 
shown that d-amphetamine is 10 times as potent as 1-amphetamine in enhancing 
locomotor activity (Taylor & Snyder, 1970). By the same token, scopolamine 
can be used in a similar fashion to assess cholinergic development because 
of its associated effects on the cholinergic mechanism. For example, if 
this system develops at different rates in the three strains, one should 
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expect scopolamine to act only on those strains and at tho'se~particular 
ages where the.cholinergic system is developed at the time_of drug 
-administration (Campbell et al, 1969). It is important to note that 
different dosages of each drug are suggested by several findings. 
Alhava and Mattila (1973), for example, report dose dependent differences 
in catecholamine levels in the brain and heart of mice measured at three 
ages postnatally following injection of amphetamine. Similarly, in a 
review of cholinergic actions, Carlton (1963) emphasizes the need of 
yC exeprimental evidence for different drugs in terms of a wider range of 
dosages and a variety of behavioural tasks. In fact, Anisman et al, 
(1974) have shown clear differences in dose response curves in different 
strains of mice, probably owing to variations in endogenous levels of 
acetylcholine, as well as in rate at which drugs are metabolized. 
Finally, the drug and strain interactions are evaluated on general 
locomotor activity. This particular measure was employed because of 
its sensitivity to pharmacological treatments. Unlike tasks involving a 
learning or memory component, drug effects are not inhibited by overriding 
cognitive factors which are often observed in aversively or appetitively 
motivated tasks (Anisman, 1974e;Longo, 1966). 
Summarizing, in the present experiment, an attempt was made to (a) 
outline the behavioural effects of d-amphetamine and scopolamine in three 
strains of mice, (b) infer the ontogenesis of catecholamine and acetyl-
choline systems from the response to pharmacological treatments, (c) 
evaluate strain-specific differences in the ontogeny of these two transmitter 
systems, and finally (d) determine whether relationships exist between 
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ontogenic and genetic variation in activity with the effectiveness of 
pharmacological treatments. 
The strains employed were^A/J, DBA/2J, and C57BL/6J mice. These 
strains were used because they represent a continuum of activity, with A 
mice exhibiting lowest levels of activity as adults, while C57 shows the highest 
levels of activity (Anisman et al, 1974). Moreover, these strains also 
show strain-specific variations in levels of acetylcholine and catecholamines. 
Specifically, C57 exhibits the lowest levels of acetylcholine and A the 
highest, whereas with respect to catecholamine activity, A mice exhibit low 
turnover rates (Bovet & Oliverio, 1973). Parenthetically, the within strain 
variability in the development of various fiber tracts in these strains 
is exceptionally small (Wahlsten, 1974a), as is the variation in response 
to drug treatments (Bovet & Oliverio, 1973). In face, it has been suggested 
that the effects of scopolamine may be modulated by a single major gene (Sco) 
(Oliverio et al, 1973). Clearly, isogenic lines may be of great benefit 
in evaluating drug effects owing to the relatively small variation seen in 
the development of fibre tracts and transmitter systems. Mice were tested 
at either 14, 21, or 28 days postpartum. These ages were selected because 
motor coordination is fairly well developed at these times (Wahlsten, 1974b), 
and in addition, substantial data exists regarding catecholamine and 
acetylcholine levels at these particular ages (Schlesinger & Griek, 1970). 
Finally, the dosages of d-amphetamine and scopolamine employed were based 
on earlier studies (Anisman & Cygan, 1974; Anisman & Kokkinidis, 1974; 
Anisman et al, 1974), indicating that these were optimal levels. 
Additionally, lower dosages than the optimal were also used in the event of 
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the blood-brain-barrier being immature at these early ages; thus, extreme 
dosage effects could be determined. The design of the present experiment 
was therefore a 3(strain) x 3(age) x 6(drug treatment) factorial in which 
all factors were considered between groups. 
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Method 
Subjects 
Subjects were 486 experimentally naive mice represented equally from 
each of three highly inbred strains (A/J, DBA/2J and C57BL/6J). Mice 
were bred at the University of Waterloo from stock originally procured 
from the Jackson Laboratory, Bar Harbor, Maine. Females were removed 
when visibly pregnant from their mating cages (16-18 days) and housed 
individually. Offspring were tested at 14, 21 or 28 days, having spent 
their neonatal periods with the maternal parent. Entire litters were 
tested on the same day in order to eliminate potential confounds owing to 
removal of one or more offspring from the breeding cage and thereby 
affecting the rest of the litter (Wahlsten, 1974). Throughout the period 
between birth and testing, ad libitum access to food, water and maternal 
parent was available. 
Apparatus 
The testing apparatus consisted of a 21 x 21 x 30 cm. clear Plexiglas 
chamber. Photoelectric cells were situated on two walls 1.0 cm. above 
the floor and spaced 7 cm. apart, thus forming a 3 x 3 matrix. Crossing a 
photobeam resulted in a count being recorded. Once a beam was broken, this 
particular cell could not be activated again until a second beam was broken, 
thereby eliminating counts due to head bobbing or tremor. Activity counts 
were recorded on a series of digital counters. 
Procedure 
At the appropriate age (14, 21 or 28 days), mice were individually 
removed from the parent cage and treated with d-amphetamine sulphate 
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,(0.5, 1.0, or 5.0 mg/kg), scopolamine hydrobromide (0.5 or 1.0 mg/kg) 
or physiological saline (2 ml/kg) (n=9/cell). All drugs were dissolved 
vin bacteriostatic water in a volume of 0.5 mg/ml. Mice were placed in 
a holding cage for a ten minute period, after which they- were put into 
the test chamber for ten minutes. During this time, activity was recorded. 
Results 
The number of photocell crossings were transformed through the 
/x + 1 in order to reduce heterogeneity of variance. The mean (± standard 
error) of the transformed scores are depicted in Figure 1 as a function of 
Strain, Age and Drug Treatment. Analysis of variance of the transformed 
Insert Figure 1 about here 
activity scores yielded a significant Strain x Age x Drug Treatment inter-
action (F=3.79, df=20/432, p<.01) (see Appendix A, Table 1). Subsequent 
Newman Keuls multiple comparisons (a=.05) were carried out on the simple 
main effects involved in this interaction, (see Appendix A, Table 3) the 
only exception to this being the case of saline treated animals. Inspection 
of the data had revealed an exceptionally large means-variance relationship 
which, owing to the extreme variance of amphetamine (5 mg/kg) groups, was 
not significantly reduced through the transformation. Indeed, the error 
variance of the overall analysis was greatly inflated by the drug groups, 
thus obscuring potential differences in saline animals whose activity 
levels and variance were relatively low. Accordingly, a separate analysis 
of variance of the activity scores for the saline treated animals was 
performed. This analysis revealed a Strain x Age interaction (F = 6.23, 
df = 4/72, p<.01) (see Appendix A, Table 2). This particular finding was 
20 
subsequently replicated (Anisman & Remington, unpublished- report). In 
any event, Newman Keuls multiple comparisons among the saline treated 
animals revealed that in all three strains, activity was greater among 
21- and 28-day-old mice than that witnessed in 14-day-old mice (see 
Appendix A, Table 4). The actual level of increase varied across the 
three strains. Specifically, at 14 days of age, DBA mice were significantly 
more active than either A or C57 mice. The increase in C57 mice at 21 
days of age was such that C57 did not differ from DBA, but both strains 
exhibited activity levels which exceeded that seen in A mice. At 28 days 
of age, a small but nonsignificant decline in activity was observed in DBA 
and C57 mice, such that C57 levels of activity, but not DBA activity, 
exceeded that observed in A mice. The decline in activity between 21 and 28 
days of age is consistent with numerous other reports indicating that 
activity reaches maximal levels at 21 days, after which a decline is noted 
toward 28 days, when activity begins to resemble that seen in adult animals 
(Campbell et al, 1969; Fibiger et al, 1970; Himwich, 1970; Mabry'& Campbell, 
19 74; Moorcroft et al, 1971; Thornburg & Moore, 1973). Indeed, among adult 
mice, it is typically observed that C57 is considerably more active than 
either DBA or A. Thus, it is not unlikely that if activity had been 
monitored at additional ages, the decline in activity would have been more 
pronounced. 
Turning to the effects of d-amphetamine and scopolamine, it was 
observed that at the 5mg/kg dosage, d-amphetamine enhanced activity in 
all strains as early as 14 days of age. In DBA, this effect did not reach 
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a significant value, as it did _in A and C57 mice. Nevertheless, effects 
of d-amphetamine were maintained at 21 and at 28 days of age. It is 
interesting to note, though, that at 14 days of age, the most pronounced 
amphetamine effect was seen in C57 mice, whereas at 21 and 28 days of age, 
amphetamine has substantially greater effects in A mice than in DBA or 
C57. The latter drug effect is precisely the same as that observed in 
adults of these strains. Evidently, although amphetamine alters activity 
as early as 14 days postnatally, the response is not comparable to that of 
adult levels. Quite possibly, maturation of the catecholamine system 
continues after 14 days of age, or the effects of the drug are modified 
with the maturation of ancillary systems which modify the effects of central 
catecholamine agents (see, for example, Swonger & Rech, 1972). A second 
interesting finding here is that at 21 days of age, vhere C57 exhibits 
maximal levels of activity, the response to amphetamine is at its lowest 
level and does not reach statistical significance. Essentially, such a 
finding suggests that although the catecholamine system is intact (witness 
the 14 day response to amphetamine), the effectiveness of amphetamine in 
increasing activity is limited by developmental factors related to 
endogenous catecholamine levels, turnover, degradation, or possibly involve-
ment of a second antagonistic system. 
The response to scopolamine was found to be very different from that 
of amphetamine. Specifically, at 14 days of age, scopolamine did not 
increase activity in any of the strains. In fact, a small but nonsignificant 
decline in activity was seen in DBA mice. However, neither A or C57 mice 
exhibited any change in behaviour in response to the drug treatment. By 
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21 days postnatally, a pronounced increase in activity was seen in response 
to both doses of scopolamine with the DBA strain; in contrast, A and C57_ 
animals revealed smaller increases which failed to reach significance. 
Finally, at 28 days of age, all three strains of mice exhibited increased 
activity levels in response to scopolamine. Quite clearly, scopolamine 
will exert disinhibitory effects on activity in all strains; however, 
the appearance of these effects becomes apparent much later than the 
amphetamine effect. In addition, the disinhibitory influence interacts 
with strain in terms of the age at which disinhibition is observed. 
It is important to note that the results presented in this paper 
have dealt exclusively with general activity. Additional data regarding 
reaction to a startle stimulus i.e., air puff, have revealed precisely 
comparable results (Remington and Anisman, unpublished report), suggesting 
that the drug effects observed here deal with general activity and 
reactivity. 
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Discussion 
Consistent with earlier reports (Anisman, 1974b,c; Anisman et al, 1974), 
.strain differences in activity levels were observed; however, the present 
data indicated that these strain differences interacted with age. At 14 
days postnatally, C57 mice exhibited minimal levels of activity relative 
to A and DBA mice. With increased development, the absolute rise in 
activity of C57 mice was such that it exceeded that observed in A mice 
and equalled that of DBA. Together with other reports involving full 
adult mice (Anisman, 1974; Anisman et al, 1974), it is apparent that 
activity in the C57 strain surpasses that seen in DBA. 
Recently, Oliverio et al (1973) have reported that activity levels, 
although inherited in a polygenic fashion, are largely controlled by a 
single autosomal gene (Exa). The observed strain differences in activity 
with age suggest either epistatic interaction, or a gene effect which 
modulates behaviour only at later stages of development. In as much as 
activity also seems to involve neurochemical maturation (Campbell & Mabry, 
1973; Carlton, 1963, 1969; Moorcroft et al, 1971), it may well be the case 
that the gene in question involves adequate neuronal transmission and/or 
maturation of enzymes associated with these transmitters. Indeed, while 
the effects exerted by this particular gene may be present, the manifesta-
tion of its behavioural consequences could be limited by differences in 
morphological development. For example, it is known that development 
of different brain structures vary across inbred strains and their various 
F^  and F£ hybrids (Wahlsten, 1974a, 1974b). This work indicated differences 
in development of areas associated with the limbic system, as well as 
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differences in growth of up to 71 different fibre tracts including both 
forebrain and hindbrain structures. 
,,. Turning to, the drug effects observed in the present investigation, it 
was observed that regardless of strain, a large increase in activity was 
observed with administration of d-amphetamine. This particular finding is 
congruent with the many earlier reports indicating adequate and early 
maturation of the hindbrain structures (Eiduson, 1971; Jackson, 1931; 
Kim et al, 1970; Moorcroft, 1971). Since d-amphetamine produces increased 
synthesis, release, and reuptake of both dopamine and norepinephrine, it 
is difficult to ascertain whether dopaminergic and noradrenergic structures 
develop differentially. Further analysis involving enzyme inhibitors such 
as a-methyl-p-tyrosine or FLA-63 may thus be crucial for determining which 
of these systems is in fact the more important one in mediating the early 
effects of amphetamine (Kellogg & Lundborg, 1973). Nevertheless, there 
are substantial data indicating that dopamine, and possibly dopamine and 
norepinephrine modulate the effects of d-amphetamine. Thus, it would 
appear safe to assume that the former of the two transmitters (and possibly 
both) are necessary for the excitatory effects of amphetamine to become 
apparent. However, the important point of the present investigation was 
that the catecholamine system was sufficiently mature at 14 days of age to 
allow for the drug effect to be apparent. 
It is of interest to note that at 14 days of age, d-amphetamine appears 
to have more potent effects on activity among C57 mice than among A or DBA 
mice. However, at 21 days of age, the full adult relationship is observed, 
in that A mice exhibit a more pronounced response to amphetamine than DBA 
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mice, which in turn exhibit a greater response than C57 mice (cf. Anisman, 
1974c, 1974d). Parenthetically, the response to d-amphetamine is apparently 
-: not-due, to-.baseline levels of ..activity, since F^ hybrids revealing high 
levels of activity, may exhibit large increments in activity with 
amphetamine treatment, whereas a cross resulting in equally high levels 
of activity may result in a small response to amphetamine. Thus, the 
actual effect of the drug is probably dependent upon neurotransmitter 
synthesis, release, reuptake, and degradation. However, the behavioural 
concomitants of the neurotransmitter status may be subject to interaction 
with other inhibitory transmitter systems (cf. Anisman, 1974c). 
In any event, the fact that highest levels of catecholamines in C57 
are seen at 21 days of age (Schlesinger & Griek, 1970) , and that this 
particular age is the one at which the smallest amphetamine effects are 
observed, is consonant with the hyperactivity hypothesis posited earlier. 
Namely, when the relations between catecholamines and acetylcholine are not 
in balance, further increases in norepinephrine may result in a rebound 
effect, or end-product-inhibition, thereby decreasing activity levels. In 
as much as the amphetamine effect is apparent at 14 and 28 days, but 
to a lesser degree at 21 days may well be due to the imbalance between 
acetylcholine and catecholamines produced by the high levels of norepine-
phrine. Specifically, at neither 14 or 28 days of age is the balance in 
serious jeopardy, and consequently amphetamine augments activity levels. 
With the imbalance at 21 days, a physiologically mediated system protects 
the organism from further disturbances in the noradrenergic-cholinergic 
balance, thereby decreasing the excitatory effects of dramphetamine. As 
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already suggested, it is not clear what the form of this p-revention is, but 
rebound effects or end-product-inhibition are not unlikely candidates. 
Turning to the effects of scopolamine, it was observed^ that in none 
of the strains was a behavioural change observed at 14 days postnatally. 
At 21 days of age, only DBA mice exhibited increased levels of activity, 
while at 28 days, scopolamine uniformly increased activity levels in all 
three strains. Quite clearly, response to amphetamine is manifested much 
earlier than to that of the anticholinergic, scopolamine. This finding is 
consistent with other reports indicating that manipulation of the noradrener-
gic system has profound effects on behaviour at an earlier age than alterations 
of the cholinergic system. Moreover, as the forebrain limbic structures are 
primarily cholinergic and the hypothalamus and midbrain structures are 
largely noradrenergic (Cooper et al, 1970), the temporal differences in the 
effects of amphetamine and scopolamine provide evidence for the caudal-rostral 
growth of the brain posited by Jackson (1931). However, the very fact that a 
differential response to scopolamine is noted across the three strains 
suggests that there are strain differences in terms of brain development, 
and in particular, cholinergic structures. 
The notion that response to anticholinergics may be related to endogenous 
levels of transmitters has been supported by research carried out in 
several labs. Specifically, in those instances where low levels of choline 
acetyltransferase and acetylcholinesterase, two enzymes indicative of 
acetylcholine levels, have been observed i.e. in the C57 strain (Ebel, 
Hermetet, & Mandel, 1972; Mandel & Ebel, 1974), negligible responsivity to 
anticholinergic agents has been reported (Abeelen & Strijbosch, 1969; 
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-Abeelen et al, 1970, 1971;"Anisman et al, 1974; Oliverio et al, 1973). 
Conversely, where higher levels of enzymes associated with acetylcholine 
have been observed, as in DBA and A mice (Bovet & Oliverio, 1973; Mandel 
& Ebel, 1974), substantial increases in activity were recorded following 
treatment with scopolamine. Thus, it is not an unlikely possibility that 
a lack of response to scopolamine in immature animals simply reflects low 
levels of acetylcholine. With the maturation of the cholinergic system, 
the effectiveness of scopolamine in increasing activity becomes apparent. 
Of particular importance here is the fact that in A and C57 mice, the 
development of the cholinergic system is retarded to that of the DBA 
strain. Interestingly enough, although scopolamine has a pronounced 
disinhibitory effect in C57 mice at 28 days of age, these effects are 
eliminated or decline in adult animals suggesting further fluctuations of 
cholinergic activity with progressive development. In any event, it is 
significant that in C57 mice, a very pronounced increase in activity is 
observed between 14 and 21 days of age. This sizeable increase may well 
be due to the lack of an inhibitory system at 21 days of age, together 
with a very pronounced increase in levels of norepinephrine (Schlesinger 
& Griek, 1970). In effect, because of the gross imbalance between 
catecholamine and acetylcholine levels, administration of amphetamine may 
produce the apparently paradoxical effect of causing only minor increases 
in activity. In A mice, the cholinergic system is also not developed; 
however, because the catecholamine levels are not changing as drastically 
as in C57, the increase in general activity between 14 and 21 days of age 
is a moderate one. Furthermore, this notion may also account for the 
28 
fact that amphetamine produces a pronounced increase in activity at 21 
days of age in A mice. Specifically, since norepinephrine levels are not 
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 Aas high as in C57, the noradrenergic-cholinergic balance is not seriously 
threatened, thus permitting the excitatory effects of amphetamine to become 
apparent. Moreover, with the development of the inhibitory cholinergic 
system by 28 days, the excitatory effects of amphetamine are dampened 
relative to that witnessed at 21 days of age. 
It would seem reasonable that although catecholamine and acetylcholine 
modifications both affect behaviour independently, these systems also act 
in a coordinated fashion. As already suggested in earlier parts of this 
paper, these two systems might interact in a homeostatic type of process, 
whereby different excitatory and inhibitory systems antagonize each other. 
Similarly, independent modifications of the two systems may result in an 
additive, and even synergistic types of effects. For example, cholinomimetics 
such as pilocarpine have been found to reduce amphetamine induced excitation, 
while anticholinergics such as scopolamine potentiate this arousal (Campbell 
et al, 1969; Fibiger et al, 1970; Thornburg & Moore, 1973). The reversal 
appears to also be true, since administration of d-amphetamine results in 
decreased levels of acetylcholine (Vasko, Domino, & Domino, 1974). 
Moreover, these data also indicate that while a distinct balance exists 
between the excitatory catecholamine and inhibitory cholinergic systems, 
the cholinergic influence lags behind noradrenergic development during 
ontogenesis, a finding in agreement with the present data. 
While it is clear that the catecholamine and acetylcholine levels 
modulate behaviour, it also seems to be the case that other putative 
transmitters are also involved, either directly or indirectly, in the proposed 
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balance model.- Suggestions have been made concerning"the jfole of the 
noradrenergic system in interaction with the serotonergic pathways. 
Specifically, para-chlorophenylalanine (p-CPA), a depletor~df"~brain 
serotonin, interacts with amphetamine to increase activity levels in a 
synergistic fashion, while administration of 5-hydroxytryptophan (5-HTP) 
prevents this effect (Ellison & Bresler, 1974; Mabry & Campbell, 1973). 
Developmentally, it is of interest to note that depletion of serotonin 
by p-CPA fails to produce such synergistic effects with amphetamine at 
10 days postnatally, although the effect is apparent by 15 days of age 
(Mabry & Campbell, 1974). Furthermore, lesions of the medial forebrain 
bundle result in dramatic reductions in telencephalic content of serotonin 
(60-84%), while at the same time producing a three-fold increase in ampheta-
mine action (Green & Harvey, 1974). 
In terms of dopaminergic pathways, it has been observed that dopamine 
receptor blocking agents, such as haloperidol, inhibit amphetamine induced 
increases in locomotor activity (Rolinski & Scheel-Kruger, 1973). In 
addition, both dopamine and norepinephrine appear to play a role in L-dopa 
induced activity increases (Maj, et al, 1971). Supporting the hypothesis 
that dopaminergic pathways are integral to noradrenergic increases in 
activity, are the findings that a-methyldopa, a substance which weakly 
stimulates dopamine receptors but has profound effects on norepinephrine, 
causes only slight increases in motor activity. If, however, it is given 
in combination with apomorphine, a dopamine receptor stimulating agent, 
substantial increases in motor activity are recorded (Anden, et al, 1973). 
Further evidence for the interaction of noradrenergic and dopaminergic 
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pathways stems -f-rom-the-reeen-fe- literature on chemical lesions using 
6-hydroxydopamine (6-0HDA). Administration of this substance sharply 
reduces brain levels of both norepinephrine and dopamine through 
destruction of their respective transmitter pathways (Ungerstedt, 1971, 
1974; Masuoka & Alcaraz, 1973; Fibiger, Phillips, & Zis, 1973; Richardson, 
1974). Following such lesions, L-dopa (the precursor of dopamine and 
norepinephrine), in combination with FLA-63 (a blocking agent of norepine-
phrine synthesis), results in increased locomotor activity (Ahlenius, 
1974). Similarly, it has been reported that amphetamine-stimulated motor 
activity and stereotyped behaviour are reduced following treatments which 
decreased dopamine or dopamine and norepinephrine. However, such 
reductions are not seen in animals where only levels of brain norepinephrine 
are reduced (Hollister, Breese, & Cooper, 1974). Further investigations 
support the hypothesis that dopamine and noradrenaline act in a combined 
fashion in modulating spontaneous motor activity (Gordon & Shellenberger, 
1973), as well as behaviours other than locomotion; for example, the 
interaction of these neurotransmitters has been related to stereotyped 
behaviours such as gnawing and continuous grooming (Molander & Randrup, 
1974), in addition to alterations in body temperature (Caccia, Cecchetti, 
Garattini, & Jori, 1973). 
The complexity of these interactions does not end here. Just as 
noradrenergic influences have been shown to interact with the cholinergic 
system (Carlton, 1963, 1969; Campbell et al, 1969; Fengley, 1974; Fibiger 
et al, 1970; Moorcroft et al, 1971; McGeer et al, 1971), it has been 
indicated that dopaminergic effects influence, at least in part, 
31 
acetylcholine. Following administration of 6-0HDA, reductions in "^ " 
acetylcholinesterase, the degrading enzyme for acetylcholine, "have been 
reported (Consolo, Ladinsky, Samanin, & Ghezzi, 1974; Grewaal,* Fibiger, 
& McGeer, 1974; Kim, 1973). In agreement with this data are findings that 
6-0HDA lesions result in large increases in acetylcholine following administra-
tion of the drug (Grewaal et al, 1974; Kim, 1973). 
Having observed these various interactions of neurotransmitter substances, 
it would seem reasonable that any pharmacological explanation of behaviour 
must involve a complex interaction of these various excitatory and 
inhibitory systems. In effect then, the suggestion here is that although 
catecholamine and acetylcholine levels serve to modulate both genetic and 
ontogenic variations in behaviour, other transmitter systems need to be 
evaluated to elucidate their role in modifying behaviour. With respect to 
phenomena such as the hyperactive syndrome, it may veil be the case that 
the aberrant behaviours observed are due, in part, to acetylcholine and 
catecholamine imbalances, but in addition, other inhibitory systems such 
as serotonin may also be poorly developed. This is expecially important 
since increased norepinephrine and/or dopamine excitation are extensively 
magnified by decreases in serotonin (Ellison & Bresler, 1974; Green & 
Harvey, 1974; Mabry & Campbell, 1973, 1974). Thus, while variation in 
response to amphetamine and scopolamine may be indicative of retarded 
development, it is not sufficient to account for the entire hyperactive 
syndrome. Quite possibly, the hyperactivity and the inverse effects of 
sympathomimetics may be more apparent in strains or individual organisms 
suffering from a lag in serotonergic ontogeny. Further work to this end is 
currently underway. 
Footnote 
While acety lchol ine is technica l ly an exc i ta to ry 
t ransmi t ter in the sense that i t induces neuronal a c t i v i t y , i t is 
referred to as an inh ib i to ry t ransmi t ter in the present document 
since i t resul ts in the reduction of ongoing locomotor behavior. 
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Figure 1. Mean transformed (i/x + 1) number of photocell crossings 
(+ standard error of the mean) as a function of Strain, 
Age and Drug Treatment. 
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APPENDIX A 
Table 1 
Analysis of Variance of Transformed Photocell Crossings (VX+1 ) 
as a Function of Strain, Age, and Drug Treatment 
Between 
Strain (S) 
Age (A) 
Drug (D) 
S x A 
S x D 
A x D 
S x A x D 
Within Cells 
Total 
df 
2 
2 
5 
4 
10 
10 
20 
432 
485 
MS 
770.62 
5714.7 
1358.8 
121.16 
77.761 
249.68 
68.506 
18.085 
F 
42.61* 
315.99* 
75.13* 
6.70* 
4.30* 
13.81* 
3.79* 
* p .01 
53 
Table 2 
Analysis of Variance of Transformed Photocell Crossings ( tfx+i ) 
for Saline Treated Animals as a Function of Strain and Age 
Between 
Strain (S) 
Age (A) 
S x A 
Within Cells 
Total 
df 
2 
2 
4 
72 
80 
MS 
104.01 
720.39 
64.499 
10.35 
F 
10.05* 
69.58* 
6.23* 
.01 
_. Table 3 
.JJewman^Keuls multiple comparisons of simple main effects 
on transformed scores ( /x+1 ) 
Sal: saline; A: amphetamine; S: scopolamine 
A - 14 days 
Drug Treatment S(1 .0) 
S(1 .0) 
S(0 .5) 
A(0.5) 
A(1.0) 
Sal 
A(5.0) 
* p .05 
q.95 ( r ,432) 
nMS q.95 ( r ,432) 
S(0 .5) 
.01 
r=2 
2.77 
3.93 
A(0.5) 
.39 
.38 
r=3 
3.31 
4.70 
A(1.0) 
1.53 
1.52 
1.14 
r=4 
3.63 
5.16 
Sal 
1.65 
1.64 
1.26 
.12 
r=5 
3 .86 
5.48 
A(5.0) 
7.36* 
7 .35* 
_. 6.97* 
5 .83* 
5 . 7 1 * 
r=6 
4.03 
5.72 
,_ -~=^. ^s=r- A - 21 dayg 
Drug Treatment - *'~ Sal A(0.5) --A(l.O)- A(5~.0) S(0.5) S(1.0) 
Sal .32 
A(0.5) 
A(1.0) 
A(5.0) 
S(0.5) 
S(1.0) 
* p .05 
3.72 
3.4 
4 .65 
4 .33 
.93 
4 .78 
4 .46 
1.06 
.13 
24 .73* 
2 4 . 4 1 * 
2 1 . 0 1 * 
20 .08* 
19 .93* 
A - 28 days 
Drug Treatment A(1.0) A(0.5) Sal S(l.O) S(0.5) A(5.0) 
A(l.O) 1.3 3.44 8.80* 9.45* 15.78* 
A(0.5) 2.14 7.50* 8.15* 14.48* 
Sal 5.36* 6.01* 12.34* 
S(l.O) .65 6.98* 
S(0.5) 6.33* 
A(5.0) 
* p .05 
5o 
DBA - 14 days 
Drug Treatment S(0.5) S(l.O) A(1.0)* Sal ' A(0.5) A(5.0)' 
.89 4.73 4.79 8.73* 8.81* 
3.84 3.90 7.84* 7.92* 
.06 4.0 4.08 
3.94 4.02 
.08 
S(0 .5 ) 
S ( l . 
A ( l . 
S a l 
.0) 
• 0 ) 
A(0.5) 
A(5. 
* P 
0) 
.05 
DBA - 21 days 
Drug Treatment A(1.0) A(0.5) Sal S(0.5) S(1.0) A(5.0) 
A(1.0) 3.67 4.34 9.17* 9.93* 15.11* 
A(0.5) .67 5.50* 8.19* 11.14* 
Sal 4.83* 7.52* 10.77* 
S(0.5) 2.69 5.94 
S(1.0) 3.25 
A(5.0) 
* p .05 
DBA - 28 days 
Drug Treatment A(l.O) Sal A(0.5) A(5.0) S(1.0) S(075)-
A(1.0) 2.60 
Sal 
A(0.5) 
A(5.0) 
S(1.0) 
S(0.5) 
* p .05 
2.78 
.18 
9.88* 
7.28* 
7.10* 
10.63* 
8.03* 
7.85* 
.75 
——— 
10.77* 
8.17* 
7.99* 
.89 
.14 
C57 - 14 days 
Drug Treatment S(1.0) Sal S(0.5) A(0.5) A(l.O) A(5.0) 
S(l.O) .15 
Sal 
S(0.5) 
A(0.5) 
A(l.O) 
A(5.0) 
.29 
.14 
1.06 
.91 
.77 
3.21 
3.06 
2.92 
2.15 
_____ 
13.12* 
12.97* 
12.83* 
12.06* 
9.91* 
* p .05 
C57 - 21 days 
Drug Treatment A(l.O) A(0.5) Sal S(1.0) S(0.5) A(5.0) 
A(1.0) .92 2.30 2.98 3.45 6.95* 
A(0.5) 1.38 2.06 2.63 6.03* 
Sal .68 1.15 4.65 
S(1.0) .47 3.97 
S(0.5) 3.50 
A(5.0) 
* p .05 
C57- 28 days 
Drug Treatment A(1.0) A(0.5) Sal S(1.0) S(0.5) A(5.0) 
A(1.0) 3.99* 5.08* 10.22* 11.65* 12.57* 
A(0.5) 1.09 6.23* 7.66* 8.58* 
Sal 5.14* 6.57* 7.49* 
S(1.0) 1.43 2.35 
S(0.5) .92 
A(5.0) 
* p .05 
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Table 4 
Newman Keuls multiple comparisons on transformed 
scores ( /X+t) for Saline Treated Animals 
* p .05 
14 days 
Strain C57 A DBA 
C57 2.03 5.06* 
A 3.83* 
DBA 
r=2 r=3 
q.95 (r,432) 2.77 3.31 
nMS q.95 (r,432) 2.96 3.54 
21 days 
Strain A DBA C57 
A 4.76* 6.08* 
DBA 1.32 
C57 
* P .05 
28 days 
Strain : . ,A • », DBA C57 
A 2.34 5.21* 
DBA 2.87 
C57 
.05 
A strain 
Age (days) 14 21 28 
14 6.41* 6.47* 
21 .06 
28 
* p .05 
o 
DBA strain 
Age (days) 14 21 28 
14 4.98* 7.34* 
21 2.36 
28 
* p .05 
C57 strain 
Age (days) 14 28 21 
14 13.71* 14.52* 
28 .81 
21 
* p .05 
( 
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Table 1 
Total Number of Photocell Crossings for Individual Subjects 
sa a Function of Age, Strain, and Drug Treatment 
A - saline 
14 days 21 days 28 days 
0 215 37 
23 86 37 
35 161 137 
56 39 139 
0 72 166 
6 133 30 
0 14 139 
15 129 138 
12 117 141 
A - amphetamine (0.5 mg/kg) 
14 days 21 days 28 days 
0 19 19 
5 29 16 
17 18 147 
0 69 41 
0 68 30 
0 36 154 
0 41 105 
51 29 25 
1 1 98 
A -
28 days 
61 
52 
27 
84 
24 
117 
53 
18 
2 
A - amphetamine (5.0 mg/kg) 
21 days 
1316 
850 
879 
1053 
1152 
571 
899 
826 
668 
65 
A - scopolamine (0.5 mg/kg) 
14 
3 
2 
18 
0 
0 
0 
0 
11 
1 
days 21 days 
99 
2 
29 
136 
164 
383 
84 
11 
47 
28 days 
112 
133 
231 
319 
360 
190 
447 
257 
345 
A - scopolamine (1.0 mg/kg) 
14 
0 
15 
8 
0 
2 
0 
0 
6 
0 
days 21 days 
78 
18 
230 
29 
533 
123 
79 
23 
71 
28 days 
172 
164 
152 
183 
286 
298 
253 
499 
186 
66 
DBA - saline 
14 days 
7 
0 
2 
330 
60 
85 
182 
107 
1 
21 days 
120 
261 
335 
71 
225 
197 
193 
255 
368 
28 days 
136 
204 
72 
179 
254 
54 
160 
162 
198 
DBA - amphetamine (0.5 mg/kg) 
14 days 
79 
23 
243 
292 
35 
7 
419 
403 
30 
21 days 
318 
259 
252 
211 
114 
61 
392 
92 
186 
28 days 
61 
395 
223 
53 
121 
224 
97 
296 
86 
DBA - amphetamine (1.0 mg/kg) 
^ ^ 21 days 28 days 
1
 69
 27 
° 16 76 
126
 189 20 
115
 130 306 
19
 52
 145 
177
 84
 95 
4
 31
 137 
292
 423
 54 
15
 159 106 
DBA - amphetamine (5.0 mg/kg) 
14_davs 21 Days 28 days 
H6 633
 396 
° 771 343 
64
 803
 392 
3
 738
 471 
309
 672 ?6 
289
 561
 690 
105 413
 633 
262
 695
 568 
371
 588 152 
68 
"'-"-"-- DBA - scopolamine (0.5 mg/kg) 
14 days" 21 days 28_days 
507 91 
39 679 
565 42 
192 727 
153 598 
522 467 
612 623 
614 500 
0 
2 
1 
10 
0 
50 
0 
1 
24 591 475 
DBA - scopolamine (1.0 mg/kg) 
14 days 21 days 28 days 
724 546 
590 255 
511 209 
358 542 
551 601 
227 237 
453 356 
573 595 
538 518 
0 
0 
0 
7 
9 
211 
0 
22 
2 
69 
14 days 
2 
4 
1 
6 
0 
0 
1 
0 
0 
21 days 
115 
222 
311 
364 
207 
326 
208 
357 
290 
28 days 
162 
251 
179 
233 
316 
245 
142 
310 
266 
C57 - amphetamine (0.5mg/kg) 
14 days 
1 
13 
0 
4 
1 
0 
1 
12 
32 
21 days 
168 
112 
191 
360 
311 
224 
97 
345 
196 
28 days 
83 
129 
174 
394 
192 
319 
185 
82 
350 
?0 
C57 - amphetamine (1.0 mg/kg) 
lJ4_daZs 21 days 28 days 
3 108 H 7 
131 119 147 
0 437 155 
74 312 181 
2
 4 31 
2 348 HI 
56 281 3 
33 150 32 
0 178 325 
C57 - amphetamine (5.0 mg/kg) 
14 days 21 days 28 days 
271 344 482 
74 421 646 
50 501 504 
570 364 626 
409 651 79 
357 254 576 
23 369 1161 
231 417 490 
141 581 402 
?i 
C57 - scopolamine (0.5 mg/kg) 
14 days 21 days 28 days 
3 345 221 
2 264 500 
2 250 563 
1 219 541 
0 64 531 
4 269 647 
1 372 418 
2 638 422 
1 392 485 
C57 - scopolamine (1.0 mg/kg) 
14 days 21 days 28 days 
1 192 195 
1 304 356 
2 208 549 
0 457 604 
0 298 474 
0 119 239 
1 293 490 
2 393 418 
1 314 493 
PRIMARY PATHWAY IN THE SYNTHESIS OF CATECHOLAMINES 
Tyrosine • (tyrosine hydroxylase) *Dopa •(dopa decarboxylase) • Dopamine »• 
(dopamine-B- hydoxylase) ^Norepinephrine ^(phenylethanolamine-N-methyl transferase) 1» 
Epinepherine. 
Note: enzymes associated with oxidation or hydrolysis are indicated in brackets. Catecholamines are 
degraded intracellularly by monoamine oxidase (MAO), and cxtracellularly by catechol-O-methyl transferase 
(COMT). (From Cooper, Bloom & Roth, 1970). 
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LATER STAGES OF SYNTHESIS AND METABOLISM OF ACETYLCHOLINE 
CITRATE GLUCOSE 
(From Cooper, Bloom & Roth, 1970) 
